Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Sexually active Chinese women, at risk for pregnancy and not planning to use condoms during trial medication use~* Women in need for contraception and willing to use a hormonal contraceptive method for 13 cycles~* Body mass index ≥18 and ≤29 kg/m\^2~Key Exclusion Criteria:~* Contraindications for contraceptive steroids~* Abnormal cervical smear corresponding to indeterminate changes at screening~* Clinically relevant abnormal laboratory result at screening as judged by the investigator.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- ENG-EE (NuvaRing) (Type: EXPERIMENTAL): Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
- DRSP-EE (Type: ACTIVE_COMPARATOR): Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.

Based on this trial design, predict the completion outcome and termination type (if applicable).